Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of paediatric-dose and standard-dose Epaxal versus Havrix Junior in children and adolescents
ISRCTN17386851Phase 2Completed
- Sponsor
- Berna Biotech AG
- Start
- Dec 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Epaxal Junior and Havrix Junior in hepatitis A (HAV) (3 arms), sponsored by Berna Biotech AG. Primary endpoint: Proportion of subjects seroprotected five years after booster vaccination. Started Dec 2006; status: completed.
02
Drugs
Epaxal JuniorHavrix Junior
03
Conditions
hepatitis A (HAV)
Beyond the preview
Go deeper on ISRCTN17386851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17386851.